Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of TAK-330 versus 4F-PCC for urgent reversal of factor Xa inhibitor anticoagulation before urgent surgery
MOH_2025-06-24_014150Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Prothromplex Total, sponsored by Takeda. Primary endpoint: Intraoperative efficacy of anticoagulation reversal. Started Apr 2025; status: recruiting.
02
Drugs
Prothromplex Total
Beyond the preview
Go deeper on MOH_2025-06-24_014150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-24_014150.